Toggle light / dark theme

15-minute Workouts May Reverse Type 2 Diabetes in Just Six Weeks

F ifteen-minute workouts could reverse diabetes in just six weeks, new research suggests. A trial of overweight men found that short, intense resistance training sessions three times a week significantly boosted their ability to manage insulin.

Previous research has indicated that 45-minute workouts could have this effect, but the new study has been greeted with particular excitement as experts believe type 2 diabetes patients will be more likely to commit to shorter sessions.

It is estimated that by 2025 there will be five million people with a diabetes diagnosis in the UK, 90 per cent of whom will have type 2, which is related to lifestyle.

Read more

Scientists relieved but wary as US shutdown ends

The shutdown dragged on two weeks longer than any other in US history, and its effects on science have been profound. It has interrupted studies of everything from California’s coastal fisheries to clinical trials of experimental drugs, and key federal data sets have been pulled offline. Employees at many science agencies were forced to stay at home without pay for more than a month, and academic researchers have been deprived of key research funding.


Federal researchers head back to work after politicians approve deal to reopen government for three weeks. Federal researchers head back to work after politicians approve deal to re-open government for three weeks.

Read more

Drug compound could be next-generation treatment for aggressive form of leukemia

Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.

Purdue University researchers are developing a series of drug that have shown promise in treating such cases. About 30 percent of AML have a mutation caused by a kinase called FLT3, which makes the more aggressive. Inhibitors of FLT3, such as Radapt, approved last year by the U.S. Food and Drug Administration, have shown good initial response to treating leukemia. Gilteritinib, another FLT3 inhibitor, was recently approved toward the end of 2018. But AML patients on FLT3 inhibitor therapy often relapse because of secondary mutations in the FLT3 and existing treatments have not been fully successful in treating those cases.

Researchers on a team led by Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry, say they have developed a series of compounds that work not only on AML with common FLT3 mutation, but also drug-resistant AML harboring problematic mutations, such as the gatekeeper F691L mutation, which some leukemia patients who relapse harbor.

Read more

UNITY Expands Human Senolytic Trial

UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee.

An expanded clinical trial

UNITY Biotechnologies, a $495 million biotech company in the process of creating senolytic medicines that target one of the aging processes, has just announced an expansion of its first-stage human trial of the first drug in its pipeline (UBX0101), which targets painful osteoarthritis of the knee.

Read more

Lowering blood pressure could cut risk factor for dementia

(CNN) — Intensive lowering of blood pressure, to a less than 120 mm Hg level, can have a measurable impact on mild cognitive impairment (MCI) — a well-established precursor of dementia, a new study finds.

Previous studies have suggested high blood pressure could be a risk factor for dementia and mild cognitive impairment, leading US researchers to explore whether lowering pressure could reduce this risk in a large randomized trial on more than 9000 people.

Lowering blood pressure did not significantly reduce dementia risk, but the secondary results showed a significant reduction in MCI, according to the study published Monday.

Read more